June 18, 2020 / 1:13 PM / 23 days ago

BRIEF-Teva Presents New Analyses Examining Changes In Migraine Disability Outcome Measurements With Ajovy Injection

June 18 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA PRESENTS NEW ANALYSES EXAMINING CHANGES IN MIGRAINE DISABILITY OUTCOME MEASUREMENTS WITH AJOVY® (FREMANEZUMAB-VFRM) INJECTION

* TEVA PHARMACEUTICAL INDUSTRIES - 14.5% TO 20% REDUCTIONS FROM BASELINE WERE REPORTED IN OVERALL HEALTH-RELATED WORK IMPAIRMENT BY END OF OPEN-LABEL EXTENSION. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below